Latest News and Comment from Education

Tuesday, January 27, 2026

HEALTHCARE ADVERTISING MAKING YOU SICK? YOU'RE NOT IMAGINING IT—YOU'RE BEING HUNTED

 

HEALTHCARE ADVERTISING MAKING YOU SICK?

YOU'RE NOT IMAGINING IT—YOU'RE BEING HUNTED

Did you just watch a commercial featuring impossibly happy people frolicking through a meadow while a soothing voice whispered, "Ask your doctor if Happylife™ is right for you"? Did your mailbox overflow with glossy brochures screaming that Medicare is about to bankrupt you unless you sign up for Medicare Advantage right this second? Did your social media feed suddenly fill with "patient success stories" after you Googled "knee pain" at 2 a.m.?

Congratulations. You're not paranoid. You're just profitable.

Welcome to 2026, where healthcare advertising has evolved from a nuisance into a full-blown epidemic—and depending on your age, you might be Patient Zero.

The Numbers Don't Lie (But the Ads Sure Do)

Let's start with the uncomfortable truth: You are being bombarded.

The average American now sees between 6 to 12 healthcare ads per day. Sounds manageable, right? Wrong. That's just the average. If you're a Boomer—the industry's favorite target—you could be seeing 16 to 20 ads daily. And if you're foolish enough to watch two hours of evening news? Buckle up for up to 40 pharmaceutical commercials in a single sitting.

That's one drug ad every seven minutes.

Women, you're not off the hook either. Big Pharma has your number—literally. Thanks to the wonders of AI-powered "precision targeting," advertisers know your age, your search history, your shopping habits, and probably your deepest insecurities. They're serving you ads for fertility treatments, migraine meds, and "wellness" supplements with the surgical precision of a heat-seeking missile.

The $26 Billion Question: Who's Paying for This?

Here's where it gets really fun: You are.

In 2024, pharmaceutical companies spent over $10.1 billion on direct-to-consumer advertising alone. When you factor in promotions to doctors (free lunches, anyone?), samples, and medical conferences, the top 10 companies dropped nearly $14 billion annually. By 2026, total digital marketing spend is expected to cross $26 billion.

But wait—there's more! (There's always more.)

The Hidden Tax

Unlike every other developed nation on Earth (except New Zealand, because apparently they also enjoy this special form of torture), the U.S. allows Big Pharma to deduct their massive advertising budgets as a "necessary business expense."

Translation: The U.S. Treasury loses over $1 billion per year in tax revenue because drug companies can write off their multi-billion-dollar ad campaigns. That's your money. Money that could go to schools, infrastructure, or literally anything else.

The Price You Pay at the Pharmacy

Think those ads are "free" because you're not paying to watch TV? Think again.

Studies show that a 10% increase in direct-to-consumer advertising is associated with a 1% to 2.3% increase in total drug spending. Advertising creates "brand loyalty" for expensive, patent-protected drugs—even when cheaper, equally effective generics exist. This "brand-switching" can cost individual patients an additional $400+ per year out of pocket.

And here's the kicker: Physicians are 17 times more likely to prescribe a specific drug if a patient requests it after seeing an ad—even if a different treatment is more clinically appropriate.

The Fab Five: Meet the Drugs Stalking Your Screen

Curious which drugs are eating up the most airtime? Here are 2025's top five most advertised medications:

1. Skyrizi (AbbVie) – $439.6 Million

The reigning champion for four years running. AbbVie runs up to 13 different commercials simultaneously to target distinct patient groups. Their "In the Picture" campaign alone cost $217 million. That's more than the GDP of some small nations.

2. Tremfya (Johnson & Johnson) – $431.0 Million

J&J nearly tripled their spending from 2024, desperately trying to steal market share from Skyrizi. Nothing says "healthy competition" like a half-billion-dollar ad war.

3. Rinvoq (AbbVie) – $376.4 Million

Skyrizi's "cousin," helping AbbVie maintain a stranglehold on daytime and evening news ad blocks. Combined, these two drugs account for over $800 million in advertising. AbbVie doesn't just buy ads—they buy entire time slots.

4. Wegovy (Novo Nordisk) – $298.1 Million

The "gold standard" weight-loss drug, advertised during the Super Bowl and awards shows. Because nothing says "healthy lifestyle" like a $1,300-per-month injection.

5. Dupixent (Sanofi/Regeneron) – $241.3 Million

Shifting heavily into TikTok and Instagram to target younger demographics. Their "Roller Disco" campaign is totally relatable, right?

The Age of Algorithmic Assault

Here's where it gets dystopian.

In 2026, pharmaceutical companies are spending more on social media and search ads than on TV. They're not just targeting "women aged 25–40" anymore. They're targeting you, specifically—based on your search history, health interests, and even anonymized health records matched with your social media profiles through "Data Clean Rooms."

The Digital Front Door

Search for "chronic joint pain" on Google, and within minutes, your Instagram and TikTok feeds will fill with "Disease Awareness" ads. These ads don't mention a drug name (clever loophole to bypass FDA rules), but they'll gently nudge you toward a telehealth consultation where—surprise!—you can get a prescription in under 30 minutes.

The Influencer Industrial Complex

Forget polished commercials. Big Pharma now hires "Patient Influencers" to share their "authentic" journey. These posts feel like friendly advice from a peer—except they're paid promotions designed to sell you expensive drugs.

What Laws Protect Us? (Spoiler: Not Enough)

The FDA has historically been about as effective at regulating pharmaceutical advertising as a screen door on a submarine. But in late 2025, something changed.

Under pressure from the "Make America Healthy Again" (MAHA) Commission and HHS Secretary Robert F. Kennedy Jr., the FDA launched what's being called a "War on Deceptive Marketing."

The Crackdown Includes:

It's a start. But it's not enough.

What You Can Do: Fight Back

You don't have to take this lying down (even if that's the position shown in most pharma ads).

Call Your Representatives

Contact your state and federal representatives and demand a total ban on direct-to-consumer pharmaceutical advertising. Remind them that the U.S. and New Zealand are the only two countries that allow this madness.

Find your representatives:

Talk to Your Doctor (Not Your TV)

If you see an ad that makes you think you need a drug, have an honest conversation with your doctor—not a rehearsed pitch. Ask about generics, lifestyle changes, and whether you actually need medication at all.

Support Legislation

Look for bills like the Protecting Patients from Deceptive Drug Ads Act and let your representatives know you support stronger regulations.

The Bottom Line

Healthcare advertising isn't just annoying—it's expensive, manipulative, and potentially dangerous. It drives up drug prices, encourages over-diagnosis, and turns the sacred doctor-patient relationship into a transactional sales pitch.

So the next time you see a commercial featuring a golden retriever and a grandmother dancing in slow motion while a voice rattles off side effects including "sudden death," remember: You're not the customer. You're the product.

And maybe—just maybe—it's time we all got a little sick of being sold sickness.

Want to learn more? Contact your representatives today and demand an end to direct-to-consumer pharmaceutical advertising. Your health—and your sanity—depend on it.



MORNING NEWS UPDATE: JANUARY 27, 2026

 

MORNING NEWS UPDATE: JANUARY 27, 2026

U.S. News
  1. Border Patrol/ICE Chief Bovino to leave Minneapolis post — Following fatal shootings by federal agents (including the recent death of nurse Alex Pretti during immigration operations), the Border Patrol chief is being reassigned, with President Trump considering reducing federal agents in Minnesota amid protests and backlash.
  2. Protests and legal challenges continue in Minneapolis over ICE tactics, including emergency lawsuits and judicial rulings against the administration's deportation push.
  3. Deep freeze and winter storm aftermath across parts of the South, with ongoing weather impacts.
  4. Private jet crash in Maine during a snowstorm kills six people.
  5. Trump Visits Iowa Amid Minneapolis Shooting Fallout: President Donald Trump is in Iowa today, shifting his focus to economic affordability and "40 weeks until the election." However, the visit is overshadowed by mounting national outrage over a fatal shooting in Minneapolis involving ICE agents and a nurse named Alex Pretti.

  6. Department of Transportation to Use AI for Regulations: In a significant shift in government operations, the Trump administration announced plans for the Department of Transportation to use Google Gemini to help draft new federal safety regulations for airplanes and cars.

  7. Massive Political Shake-up in Iowa: With Republican Governor Kim Reynolds and Senator Joni Ernst opting out of re-election bids, today marks a historic shift in Iowa politics. This is the first time since 1968 that both a governor and U.S. senator seat are open simultaneously in the state.

  8. Controversial Appointments in Chile: Human rights groups are criticizing President-elect José Antonio Kast’s selection of former Pinochet lawyers for his cabinet, a move that is making waves in U.S. diplomatic circles.

Politics
  1. Trump administration faces scrutiny over ICE shootings — Including the sacking/reassignment of officials and court summons for ICE leaders amid accusations of violations.
  2. Trump threatens 25% tariffs on South Korea imports, citing delays in trade deal codification, impacting global trade relations.
  3. Trump pushes plan to cap credit card interest rates at 10%.
  4. Supreme Court and judicial developments — Including arguments on privacy laws and immigration case backlogs.
World Affairs
  1. Israel recovers the body of the last hostage in Gaza, clearing the way for the next phase of a Trump-brokered ceasefire.
  2. EU and India sign landmark free trade agreement — Tariffs slashed on most goods (including autos, spirits, textiles), accelerated amid Trump's tariff threats; hailed as one of India's largest deals.
  3. Apparent North Korean missile test reported.
  4. Trump tariff threats extend to other partners, with pledges of trillions in investments from allies like EU, Japan, and South Korea under scrutiny for feasibility.
  5. International Holocaust Remembrance Day: Nations around the world are holding ceremonies today to mark the anniversary of the liberation of Auschwitz. The U.S. State Department issued a formal commemoration led by Secretary of State Marco Rubio.

  6. U.S. Formally Withdraws from the WHO: Following through on campaign promises, the Trump administration has officially terminated U.S. membership in the World Health Organization, signaling a major shift in global health diplomacy.

  7. Middle East Waste Crisis: A new World Bank report released today warns that the waste crisis in the Middle East and North Africa is causing $7.2 billion in environmental damage annually, threatening regional tourism and economic growth.

Education
  1. U.S. News & World Report releases 2026 Best Online Programs rankings — Highlighting top programs (e.g., University of Florida at #1 for bachelor's, various schools rising in master's categories like educational administration).
  2. NC State College of Education ranks #18 nationally in online master's programs, up from previous years.
  3. Ongoing debates on math teaching and college readiness — Including senatorial inquiries into student preparation for college-level math.
  4. 2026 Best Online Programs Rankings Released: U.S. News & World Report published its annual rankings today. The University of Florida took the #1 spot for online bachelor's programs, while Indiana University–Bloomington led for online MBAs.

  5. Universities Launch "Fight Back" Campaign: A group of major U.S. colleges launched a national advertising campaign titled "College: Proud Sponsor of America at Its Best" to counter a decade of declining public trust and recent political attacks on higher education funding.

Economy
  1. Global stocks hit record highs despite trade angst — Earnings hopes from Big Tech (e.g., upcoming reports from Microsoft, Apple, Tesla) offset tariff concerns; gold and silver climb.
  2. U.S. markets close higher — Dow at ~49,412, S&P 500 at ~6,950, Nasdaq at ~23,601, with gains in tech and other sectors.
  3. Trump's investment pledges from trading partners total trillions (e.g., $5T+ from EU, Japan, etc.), but researchers question the figures and economic impact.
  4. Criticism of Trump's economic approach as highly interventionist, potentially derailing long-term growth.
  5. Federal Deregulation Push: The National Credit Union Administration (NCUA) announced its fourth round of deregulation proposals today, aiming to eliminate "unduly burdensome" requirements for credit unions to bolster liquidity.

  6. Tariff Warnings for South Korea: President Trump has signaled new potential tariffs on South Korea, citing frustrations with delays in renegotiating existing trade deals.

Technology
  1. Big Tech earnings week begins — Pressure to show AI bets (infrastructure, cloud growth) translating to revenue; Alphabet surges on AI model reception.
  2. EU pushes Google to share AI and search data under new tech regulations.
  3. Record technology investments in manufacturing — But AI skills gaps create bottlenecks for U.S. workforce readiness.
  4. Quantum hybrid systems testingAQT Arithmos announces real-world program starting March 2026.
  5. Quantum Hybrid Testing Program: AQT Arithmos announced today that it will begin real-world testing of quantum-classical hybrid systems this March, a critical step in moving quantum computing from the lab to practical industry use.

  6. Dexterous Robotics Breakthrough: Researchers at Kennesaw State University, supported by the NSF and NVIDIA, unveiled new progress in "human-touch" robotics, enabling robotic hands to perform complex tasks with human-like precision.

Health
  1. Breakdown in CDC vaccine and disease tracking databases — Many outdated or delayed in 2025, leaving U.S. vulnerable to outbreaks and pandemics.
  2. Syphilis cases soaring among pregnant people.
  3. Study: Lack of exercise linked to higher chronic stress in middle age.
  4. Vigil and tributes for nurse Alex Pretti — Killed in ICE-related shooting, highlighting immigration enforcement's health impacts.
  5. The Rise of "AI Scribes": A new health report today highlights the rapid adoption of ambient AI scribes in doctors' offices, which take notes during exams to allow physicians to focus entirely on patients rather than computer screens.

  6. Long-COVID Research Update: New federal research released today suggests a link between long-term COVID-19 complications and accelerated brain aging, leading to calls for renewed focus on dormant virus fragments.

Sports
  1. Arizona remains unanimous No. 1 in AP Top 25 men's college basketball poll — Ahead of showdown with No. 13 BYU.
  2. NBA matchups — Including Bucks vs. 76ers (with Milwaukee shorthanded without Giannis Antetokounmpo).
  3. Athletes protest fatal Minneapolis shooting — WNBA's Breanna Stewart and others demonstrate against ICE actions.
  4. Local/regional games — Various college and pro events ongoing, including hockey and basketball in areas like South Dakota.
  5. Australian Open Updates: In Melbourne, Iga ÅšwiÄ…tek continued her dominant march toward a career Grand Slam with a fourth-round victory over Madison English.

  6. World Cup 2026 Preparation: With the FIFA World Cup arriving later this year, the U.S. State Department and FIFA organizers released an updated security and logistics framework today for host cities.

  7. Bradman Memorabilia Record: A test cricket cap worn by legend Sir Donald Bradman sold at auction today for $533,000, setting a new record for sports memorabilia in that category.

These reflect the most recurring and prominent stories circulating today, with heavy focus on U.S. immigration fallout and international trade dynamics.